American biopharmaceutical leader in antiviral drugs
The US is ending its global health supply program, risking shortages of HIV and malaria medicines in Africa and Haiti. The transition to new procurement methods is uncertain, with potential gaps in life-saving supplies amid ongoing aid reductions and policy shifts.
South Africa has begun a six-month injectable PrEP rollout using lenacapavir, with officials highlighting equity goals while civil society urges broader access. Reports note clinics have seen benefits and challenges from the new prevention tool and ongoing gaps in specialised services.